comparemela.com

Page 10 - இணக்கம் ஆய்வுகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The SEC s 2021 Examination Priorities Provide Firms With a Roadmap to Compliance | Orrick, Herrington & Sutcliffe LLP

To embed, copy and paste the code into your website or blog: Last week, the Securities and Exchange Commission’s newly renamed Division of Examinations (formerly known as the Office of Compliance Inspections and Examinations) published its 2021 Examination Priorities (“Exam Priorities”). This annual guidance reports on the Division’s accomplishments and rates of examinations for the prior year, and seeks to promote compliance, prevent fraud, identify and monitor risk, and inform policy. It provides industry participants with a road map to plugging any gaps in their compliance. Many of the Exam Priorities are perennials for example, those related to broker-dealer sales practices and treatment of seniors, and registered investment adviser compliance programs but these are supplemented by the Division’s focus on risks that have emerged in recent years, including information security, digital assets, and operational resiliency in light of climate-change related risks. This

SEC Division of Examinations Announces 2021 Examination Priorities | Troutman Pepper

To embed, copy and paste the code into your website or blog: On March 3, the U.S. Securities and Exchange Commission’s (SEC) Division of Examinations (Division), formerly known as the Office of Compliance Inspections and Examinations, announced its examination priorities for fiscal year 2021. The Division publishes the report annually to identify areas where it believes potential risks to investors and U.S. capital markets may exist. This year’s report focused particularly on climate-related risks, conflicts of interests for brokers and investment advisers, and attendant risks related to fintech. Below find a summary of the Division’s 2021 examination priorities.

A Busy Week in Pennsylvania Hospital Markets: In Philly, the FTC Ends Its Jefferson-Einstein Merger Challenge and in Central PA, the DOJ Proposes to Resolve Its Geisinger-Evangelical Collaboration Agreement With a Consent Decree | Saul Ewing Arnstein & Lehr LLP

To embed, copy and paste the code into your website or blog: The U.S. Department of Justice (“DOJ”) and the Federal Trade Commission (“FTC”), in the span of about 48 hours in the first days of March, wrapped up two challenges to hospital deals – one dropped, the other settled (pending court approval). Both outcomes should be viewed as important indicators of both the issues the enforcement agencies are likely to focus on in health care industry deals and why market definition is particularly critical in health care market transactions.  The Philadelphia Case On Monday, March 1, the FTC announced that it was walking away from its year-old challenge to the pending merger of the Philadelphia-area Jefferson Health (“Jefferson”) and Albert Einstein Healthcare Network (“Einstein”). The case was filed in February 2020, and the FTC was joined by the Pennsylvania Office of Attorney General (“PA-AG”). The FTC and PA-AG, unsuccessfully, sought a preliminary injunction

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.